China Housing Demand to Stay at 75% Below Peak, Goldman Says
China's demand for new homes in cities is expected to stay at 75% below its 2017 peak in the coming years due to a shrinking population and expectations of price declines that have been hurting investment interest, according to Goldman Sachs Group Inc.
'Falling population and slowing urbanization suggest decreasing demographic demand for housing,' Goldman Sachs analysts wrote in a report. 'Investment demand in China could turn negative as owners sell vacant apartments.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Hedge funds' bets on Asia hit five-year high, says Goldman
By Summer Zhen and Nell Mackenzie HONG KONG (Reuters) -Global hedge funds posted their biggest jump in trading volumes across Asian markets in over five years last week, a Goldman Sachs note showed. Funds were buying and short-selling, with bullish positions in Asia between June 6 and June 12 hitting their highest level since September 2024 - outpacing bearish bets, said the Goldman note, published on Friday and seen by Reuters on Tuesday. Hedge funds bought equities in Japan, Hong Kong, Taiwan and India last week, but were short selling onshore Chinese stocks, Goldman said. Asian stocks extended their strong rally in June as high-level trade talks between U.S. and China in London raised hopes for a de-escalation of the trade war, while South Korea's election of a market-friendly new president boosted capital inflows. Market participants pointed out the trend of de-dollarization as a hedge against further declines in the U.S. dollar also benefited broad Asian markets. "If you are an international investor, you might start to rotate back to either your own markets or Asia that has been under appreciated," said Kier Boley, co-head and CIO of UBP Alternative Investment Solutions. The MSCI Asia-Pacific Index has risen 2.5% this month ,led by gains in Korea and Taiwan stocks. The benchmark has surged 24% since April 7, driven by a 90-day pause on higher U.S. tariffs and signs of progress in trade negotiations. The share of developed Asia markets in hedge funds' total exposure tracked by Goldman rose to 9%, ranking in the 94th percentile in the past five years, Goldman said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
26 minutes ago
- Bloomberg
Foshan Haitian Raises $1.3 Billion in Upsized Hong Kong Listing
Foshan Haitian Flavouring & Food Co. has raised HK$10.1 billion ($1.3 billion) after robust demand for its shares to be listed in Hong Kong allowed China's biggest soy sauce maker to increase the deal size. The company, whose shares already trade in Shanghai, sold 279 million shares at HK$36.30 each, the top end of the marketed price range, according to terms of the deal seen by Bloomberg News. That reflects a roughly 17% discount to Foshan Haitian's Monday closing price of 40.12 yuan in Shanghai.
Yahoo
37 minutes ago
- Yahoo
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase I clinical trial evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. "We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating the differentiated value of our validated Trimer-Tag platform," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3). Thus, we look forward to the clinical trial results for our respiratory combination vaccine candidates in order to maximize our impact on public health globally." In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01E-adjuvanted RSV vaccine (AREXVY), and results indicated a potential best-in-class combined immunogenicity & tolerability profile of SCB-1019. These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform. The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3) or SCB-1019 (RSV) comparator. The study will assess safety, reactogenicity and immunogenicity. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. View original content: SOURCE Clover Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
